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Objectives This study sought to compare the action of prasugrel and ticagrelor in ST-segment elevation myocardial infarc-
tion (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI).
Background It has been documented that prasugrel and ticagrelor are able to provide effective platelet inhibition 2 h after a
loading dose (LD). However, the pharmacodynamic measurements after prasugrel and ticagrelor LD have been
provided by assessing only healthy volunteers or subjects with stable coronary artery disease.
Methods Fifty patients with STEMI undergoing PPCI with bivalirudin monotherapy were randomized to receive 60 mg pra-
sugrel LD (n  25) or 180 mg ticagrelor LD (n  25). Residual platelet reactivity was assessed by VerifyNow at
baseline and 2, 4, 8, and 12 h after LD.
Results Platelet reactivity units (PRU) 2 h after the LD (study primary endpoint) were 217 (12 to 279) and 275 (88 to
305) in the prasugrel and ticagrelor groups, respectively (p  NS), satisfying pre-specified noninferiority criteria.
High residual platelet reactivity (HRPR) (PRU 240) was found in 44% and 60% of patients (p  0.258) at 2 h.
The mean time to achieve a PRU 240 was 3  2 h and 5  4 h in the prasugrel and ticagrelor groups, respec-
tively. The independent predictors of HRPR at 2 h were morphine use (odds ratio: 5.29; 95% confidence interval:
1.44 to 19.49; p  0.012) and baseline PRU value (odds ratio: 1.014; 95% confidence interval: 1.00 to 1.03;
p  0.046).
Conclusions In patients with STEMI, prasugrel showed to be noninferior as compared with ticagrelor in terms of residual
platelet reactivity 2 h after the LD. The 2 drugs provide an effective platelet inhibition 2 h after the LD in only a
half of patients, and at least 4 h are required to achieve an effective platelet inhibition in the majority of pa-
tients. Morphine use is associated with a delayed activity of these agents. (Rapid Activity of Platelet Inhibitor
Drugs Study, NCT01510171) (J Am Coll Cardiol 2013;61:1601–6) © 2013 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.024Current guidelines recommend prasugrel and ticagrelor in
patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary inter-
vention (PPCI) (1,2). The rapid onset of actions of prasu-
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012, accepted January 8, 2013.grel or ticagrelor may maximize the benefit of bivalirudin
therapy in STEMI patients undergoing PPCI, and poten-
tially decrease the risk of acute stent thrombosis. In fact, it
has documented that prasugrel and ticagrelor are able to
provide effective platelet inhibition after very few hours (2 h)
from loading dose (LD) administration. However, the
pharmacodynamic measurements after prasugrel and ti-
cagrelor LD have been provided by assessing only healthy
volunteers or subjects with stable coronary artery disease
(3–7). On the contrary, PPCI for STEMI is the clinical
arena in which rapid onset of antiplatelets effect is pivotal,
especially when a strategy without intravenous antiplatelets
agents is adopted.
Thus, the aim of the RAPID (Rapid Activity of Platelet
Inhibitor Drugs) study was to compare the action of prasugrel
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STEMI undergoing PPCI with
bivalirudin monotherapy.
Methods
Study design. The RAPID study
was a randomized, 2-arm, pro-
spective study. The study was
approved by the local ethical
committee. All patients gave in-
formed written consent. The
study flow-chart is reported in
Figure 1.
Patient population. Fifty pa-
tients with STEMI were ran-
domized to receive 60 mg prasu-
grel LD (n  25) or 180 mg
ticagrelor LD (n  25) before
PCI. The LD were performed as soon as possible in the
mergency Room or in the Cath Lab. Dual antiplatelet
herapy (100 mg aspirin associated with 5 or 10 mg
rasugrel or 180 mg ticagrelor) was recommended for 12
onths. Study inclusion criteria were diagnosis of STEMI
ithin 12 h of symptoms onset and informed written
onsent. Exclusion criteria were the following: 1) age 18
ears; 2) active bleeding or bleeding diathesis; 3) any
revious transient ischemic attack/stroke; 4) administration
n the week before the index event of clopidogrel, ticlopi-
ine, prasugrel, ticagrelor; 5) known relevant hematological
Abbreviations
and Acronyms
CI  confidence interval
HRPR  high residual
platelet reactivity
LD  loading dose
LTA  light transmittance
aggregometry
OR  odds ratio
PPCI  primary
percutaneous coronary
intervention
PRU  platelet reactivity
units
STEMI  ST-segment
elevation myocardial
infarction
Figure 1 Patient Flow and Study Design
Number of patients screened and finally enrolled in each study arm (upper panel)
PRU  platelet reactivity units; TIA  transient ischemic attack.eviations; 6) life expectancy 1 year; or 7) known severe
iver or renal disease.
oncomitant medications: The following were concomi-
ant medications: 1) aspirin: 500 mg LD followed by 100
g daily dose; 2) bivalirudin: bolus 0.75 mg/kg followed by
.75 mg/kg/h infusion during PCI, after PPCI a bivalirudin
nfusion of 0.25 mg/kg/h for 4 h was allowed; 3) unfrac-
ionated heparin use was discouraged; and 4) glycoprotein
Ib/IIIa inhibitors were not allowed.
latelet function tests. Residual platelet reactivity was
ssessed at baseline (time of LD), and after 2, 4, 8, and 12 h
y VerifyNow. High residual platelet reactivity (HRPR)
as defined as a platelet reactivity units (PRU) 240.
nhibition of platelet aggregation was defined as the per-
entage decrease in aggregation values obtained at baseline
nd after treatment: 100  (PRU baseline – PRU after
rug)/PRU baseline. Moreover, platelet reactivity was also
ssessed by light transmittance aggregometry (LTA)
APACT4, Helena Laboratories, Milan, Italy), using 10
M ADP as agonist, 12 to 24 h after drug LD as previously
reported (8).
Endpoints. The primary study endpoint was residual plate-
let reactivity by PRU VerifyNow 2 h after LD. Secondary
endpoints were the following: 1) percentage of patients with
an HRPR 2 h after LD; 2) acute stent thrombosis; and 3)
in-hospital Thrombolysis In Myocardial Infarction major,
minor, or minimal bleedings.
Sample size calculation. The study was designed on the
basis of the noninferiority principle. As compared with
ling schedule (lower panel).. Samp
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April 16, 2013:1601–6 Prasugrel and Ticagrelor in STEMIticagrelor, prasugrel may carry some little advantages in-
cluding 1 daily dose, reduced cost, and a limited number of
patients having dyspnoea. Thus, we hypothesized that
prasugrel would be noninferior as compared with ticagrelor.
We assumed that the primary endpoint (PRU at 2 h) would
be 55  40 in the ticagrelor group, and 72  40 in the
prasugrel group. We admitted a noninferiority limit of 35.
The planned enrollment of 50 patients provides 90% power
for detecting this PRU difference at an alpha level of 0.05.
Statistical analysis. Continuous data are expressed as
mean  SD or medians (quartiles) as appropriate, and
ategorical data as proportions (%). Data were compared by
eans of the chi-square test for categorical variables and
npaired Student t test or Mann-Whitney U test for
ontinuous variables. To control for type I error in multiple
omparisons, the Bonferroni-adjusted significance level was
sed for the 5 time points of PRU assessment. We per-
ormed the analysis of variance for repeated measures of
RU at different times to test equality of means. The
ultivariable analysis used to evaluate the independent
ontribution of clinical characteristics to HRPR at 2 h was
erformed by the forward stepwise binary logistic regression
nalysis. The variables entered into the model were age
years), body mass index, diabetes mellitus, left ventricular
Baseline Characteristics of Study PatientsTable 1 Baseline Characteristics of Study P
Variable
Prasu
(n 
Age, yrs 67
Male 20 (80
Body mass index, kg/m2 27
Smoker 9 (36
Hypertension 15 (60
Dyslipidemia 5 (20
Diabetes mellitus 6 (24
Previous myocardial infarction 1 (4%
Previous PCI 1 (4%
Previous CABG 0 (0%
Systolic blood pressure, mm Hg 146
Heart rate, beats/min 73
Left ventricular ejection fraction, % 44
Creatine kinase peak value, U/l 1,501 (44
Time creatine kinase peak, h 6 (3–
Anterior infarct location 8 (32
Cardiogenic shock 2 (8%
Unfractionated heparin bolus 4 (16
Thrombectomy 19 (76
Infarct artery stenting 25 (10
Morphine use 12 (48
Vomit 2 (8%
Discharge therapy
Aspirin 23 (92
ACE inhibitors 20 (80
Beta-blockers 20 (80
Statins 23 (92
Proton pump inhibitors 22 (88Values are mean  SD, n (%), or median (quartiles).
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass grajection fraction, cardiogenic shock, morphine use, random-
zation arm, and baseline PRU value. A significance of 0.05
as required for a variable to be included in the multivariate
odel, whereas 0.10 was the cutoff value for exclusion. Odds
atios (ORs) and 95% confidence intervals (CIs) were calcu-
ated. A p value 0.05 was considered statistically
ignificant. All tests were 2-sided, except the noninferi-
rity test. Analyses were performed with SPSS version 19
IBM Corporation, Somers, New York).
esults
aseline and procedural characteristics. The 2 groups
ere well matched in all baseline characteristics (Table 1).
he study drug LD was performed in 18 (36%) patients
n the Emergency Room, and in 32 (64%) patients in the
ath Lab, without differences between the 2 groups.
even patients received 5,000 UI of unfractionated hep-
rin in the Emergency Room, with subsequent switching
o bivalirudin.
esidual platelet reactivity. After 2 h, PRU values ranged
rom 2 to 398 (median: 242 [54 to 293]). There was no
ifference in PRU value at 2 h between prasugrel and
icagrelor group: 217 (12 to 279) and 275 (88 to 305),
ts
Ticagrelor
(n  25) p Value
67 10 0.998
19 (76%) 0.733
26 4 0.690
9 (36%) 1
18 (72%) 0.370
10 (40%) 0.123
3 (12%) 0.269
3 (12%) 0.297
3 (12%) 0.297
0 (0%) 1.000
146 29 0.931
81 28 0.266
41 12 0.266
4) 2,038 (550–3,399) 0.632
6 (3–7) 0.910
12 (48%) 0.248
5 (20%) 0.221
3 (12%) 0.684
16 (64%) 0.355
25 (100%) 1.000
9 (36%) 0.390
1 (4%) 0.552
22 (88%) 0.637
19 (76%) 0.733
15 (60%) 0.123
22 (88%) 0.637
20 (80%) 0.468atien
grel
25)
14
%)
4
%)
%)
%)
%)
)
)
)
33
14
10
6–3,48
11)
%)
)
%)
%)
0%)
%)
)
%)
%)
%)
%)
%)fting; PCI  percutaneous coronary intervention.
b
A
g
H
b
m
c
a
(
p
F
3
g

t
o
C
1
I
r
b
c
T
h
h
D
T
s
t
1604 Parodi et al. JACC Vol. 61, No. 15, 2013
Prasugrel and Ticagrelor in STEMI April 16, 2013:1601–6respectively (p 0.207). Prasugrel showed to be noninferior
as compared with ticagrelor in inhibiting platelet activity 2 h
after the LD (: 41; 95% CI: 115 to 31; which was
ehind the predefined 35 noninferiority margin) (Fig. 2).
t 8 h, PRU value was significantly lower in the prasugrel
roup as compared with the ticagrelor group (Fig. 3).
owever, the analysis of variance showed not significant
etween-subjects treatment effect (p  0.338), and treat-
ent by time interaction effect (p  0.744). We also
alculated inhibition of platelet aggregation values that are
ble to correct for potential differences in baseline PRU
Fig. 4). The percentage of HRPR patients at different time
oints in the prasugrel and ticagrelor groups are reported in
igure 5. Residual platelet reactivity evaluated by LTA was
4 14 and 39 14 (p 0.215) in prasugrel and ticagrelor
roups, respectively. The mean time to achieve a PRU
Figure 2 Primary Endpoint Absolute Difference
and 2-Sided 95% Confidence Interval
Platelet reactivity units at 2 h absolute difference and 2-sided 95% confidence
interval between ticagrelor and prasugrel. Tinted area indicated zone of inferior-
ity. The pre-specified limit of noninferiority was 35.
Figure 3 Kinetics of Platelet Inhibition Over Time
Residual platelet reactivity values assessed by platelet reactivity units Veri-
fyNow at baseline and 2, 4, 8, and 12 h after drug loading dose in patients
with prasugrel (triangles) and ticagrelor (squares). *p  0.01 versus Ticagre-
lor. †p  0.01 versus baseline, ‡p  0.01 versus 2 h.240 was 3  2 h and 5  4 h in the prasugrel and
icagrelor groups, respectively. The independent predictors
f HRPR 2 h after LD were morphine use (OR: 5.29; 95%
I: 1.44 to 19.49; p 0.012) and baseline PRU value (OR:
.014; 95% CI: 1.00 to 1.03; p  0.046).
n-hospital outcome. The clinical events observed are
eported in Table 2. There was no difference in event rates
etween the 2 study drugs, but a higher rate of dyspnoea and
ontrast-induced nephropathy in the ticagrelor group.
here were 2 deaths in the ticagrelor group due to refractory
eart failure. One patient with HRPR after prasugrel LD
ad a stent thrombosis 3 h after PPCI.
iscussion
he study results can be summarized as follows: 1) prasugrel
howed to be noninferior as compared with ticagrelor in
erms of residual platelet reactivity 2 h after the LD; 2) 2 h
Figure 4 Inhibition of Platelet Aggregation Over Time
Inhibition of platelet aggregation by VerifyNow at 2, 4, 8, and 12 h after drug
loading dose in patients with prasugrel (triangles) and ticagrelor (squares).
*p  0.01 versus ticagrelor.
Figure 5 Patients With High Residual
Platelet Reactivity Over Time
The percentage of high residual platelet reactivity (HRPR) patients at different
time points in the prasugrel (green bars) and ticagrelor (orange bars) groups.
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April 16, 2013:1601–6 Prasugrel and Ticagrelor in STEMIafter a LD of the new P2Y12 receptor inhibitors a wide
variability in drug response must be expected in STEMI
patients, and the PRU values are higher than those reported
for healthy volunteers or subjects with stable coronary artery
disease; 3) one-half of STEMI patients treated with a LD
of prasugrel or ticagrelor show HRPR after 2 h, and at least
4 h are required to achieve a sufficient drug effect; and 4)
morphine use is associated with a delayed activity of the new
oral antiplatelet agents.
Platelet function test results in STEMI patients treated
by prasugrel or ticagrelor LD are scarce; in fact, the
pharmacodynamic substudies of the TRITON–TIMI-38
(Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel—Thrombolysis in
Myocardial Infarction-38) (5) and PLATO (Platelet Inhi-
bition and Patient Outcomes) trials (9) included only 4 and
5 patients with STEMI, respectively. Our data revealed a
wide variability of drug response suggesting that the gastro-
intestinal absorption of orally administered drugs may be
limited or delayed in STEMI patients because of multiple
reasons including reduced or delayed drug adsorption in
patients with hemodynamic disarrangement, systemic vaso-
constriction, adrenergic activation, and at high risk of vomit.
Moreover, advanced age, high body weight, and polyphar-
macotherapy may be additional parameters potentially able
to influence the time of drug effect onset (10,11). The PRU
findings obtained in the present study were clearly higher
than that observed in previous studies, which analyzed
prasugrel or ticagrelor pharmacokinetic data in healthy
volunteers or subjects with stable coronary artery disease
(3–7). Of note, more than a half of patients treated with the
new antiplatelet agents still show HRPR 2 h after the LD.
This means that the majority of the procedures of stenting
of the infarct-related artery were performed without func-
tional evidence of a significant antiplatelet effect. In a
previous study, it has been demonstrated that a nontrivial
number of acute coronary syndrome patients do not achieve
optimal platelet inhibition despite the use of prasugrel LD
and that such patients have a higher risk of major adverse
cardiac events (12). Moreover, given the fact that HRPR is
In-Hospital OutcomesTable 2 In-Hospital Outcomes
In-Hospital Events
Prasugrel
(n  25)
Ticagrelor
(n  25) p Value
Death 0 (0%) 2 (8%) 0.149
Myocardial infarction 1 (4%) 0 (0%) 0.312
Stent thrombosis 1 (4%) 0 (0%) 0.312
Stroke 0 (0%) 0 (0%) 1.000
TIMI major bleeding 0 (0%) 0 (0%) 1.000
TIMI minor bleeding 0 (0%) 3 (12%) 0.074
TIMI minimal bleeding 0 (0%) 2 (8%) 0.149
Dyspnoea 0 (0%) 5 (20%) 0.018
Contrast-induced nephropathy 0 (0%) 5 (20%) 0.018
Values are n (%).
TIMI  thrombolysis in myocardial infarction.an important determinant of the risk of stent thrombosis,and that the majority of STEMI patients require at least 4 h
to achieve a sufficient drug effect after a prasugrel or
ticagrelor LD, we can imagine a significant time window
after PPCI, in which many patients are at high risk of stent
thrombosis. Thus, all these findings raise the question for
the need of different pharmacological strategies in the first
hour after STEMI onset. Regarding the comparison of the
2 drugs, prasugrel, despite being adsorbed as a prodrug, was
noninferior as compared with ticagrelor in reducing the
primary endpoint of the study of residual platelet reactivity
2 h after the LD. We do not know if the differences
obtained in PRU values between the 2 study drugs may be
related to not statistically significant (e.g., cardiogenic
shock) or unmeasured differences in the baseline character-
istics of the 2 groups, or may be associated to the fact that
ticagrelor LD is just the daily dose, while prasugrel LD is
6-fold the chronic daily dose. As expected, baseline PRU
value resulted as a predictor of HRPR 2 h after drug LD.
Thus, higher is the activation of the platelet in STEMI
patients before treatment and more time the new antiplate-
let drugs take to achieve a sufficient platelet inhibition.
Finally, morphine use resulted to be associated with a
delayed activity of the new oral antiplatelet agents. We do
not know if it is only a play of chance or if it has biological
basis likely related to the inhibition of the normal muscular
activity of the stomach and the intestines, which may lead to
vomit or delayed drug adsorption. However, if these find-
ings will be confirmed by further studies, more caution
should be used regarding morphine administration in
STEMI patients.
Study limitations. First, the small sample size is certainly
its most important limitation. However, we were able to
enroll a prospective homogenous populations of patients with
STEMI that mirrors other similar studies, and clinical out-
come data were reported only as indicative. Second, we
evaluated residual platelet reactivity by only 1 test
(VerifyNow) that was available in our Hospital 7/7 days and
24/24 h allowing the enrollment of consecutive patients.
LTA data were available only 12 to 24 h after drug LD and
confirmed similar and optimal platelet inhibition of prasu-
grel and ticagrelor at that time point. Third, the PRU values
were measured in STEMI patients treated with bivalirudin
monotherapy and it is unknown if they can be extrapolated
to patients treated with different pharmacological strategies.
Finally, overfitting risk cannot be excluded in our multivari-
able model.
Conclusions
These limitations notwithstanding, the present study pro-
vides several unique and potentially important insights in
the treatment of STEMI patients by PPCI.
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